Breaking News
Sort by:
Top Post
Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease
An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]
Phio Pharmaceuticals Presents Preclinical Study Showing INTASYL™ Treatment of NK Cells More than Doubles Ability to Kill Tumor Cells
Phio Pharmaceuticals, a clinical-stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to […]
Asieris Deepens Strategic Partnership with UroViu to Further Develop Integrated Diagnosis and Treatment Platform for Bladder Cancer
Asieris Pharmaceuticals, a global biopharma company specializing in discovering, developing and commercializing innovative drugs for […]
Janux Therapeutics Announces First Patient Dosed with JANX008 in First-in-Human Phase 1 Clinical Trial in Patients with Solid Tumors
Janux Therapeutics, a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying […]
ZAP Surgical Announces 1,000th Patient Treated with Its Groundbreaking ZAP-X Gyroscopic Radiosurgery Platform
ZAP Surgical Systems, a leading innovator in the field of surgical robotics, today announced that […]
MapKure, BeiGene and SpringWorks Present Clinical Data on BGB-3245, a Selective Next-Generation B-RAF Inhibitor, in Adult Patients with Advanced or Refractory Solid Tumors
MapKure, BeiGene and SpringWorks Therapeutics, today announced that they will present updated clinical data from the […]
CTRL Therapeutics Launches with $10M Seed Financing to Advance Next-Generation Cell Therapy Platform for the Treatment of Solid Tumors
CTRL Therapeutics, a biotechnology company developing a next-generation cell therapy platform for solid tumors, has […]
Porton Advanced and Bennu Biotherapeutics Announced a Strategic Partnership to Accelerate Cell Therapy Development for Solid Tumors
Porton Advanced Solutions and Bennu Biotherapeutics have announced a strategic partnership to advance cell and […]
Fore Biotherapeutics Announces First Patient Dosed in Global Phase 2 Trial Evaluating FORE8394 in BRAF-Mutated Solid and Brain Tumors
Fore Biotherapeutics, a precision oncology company dedicated to developing innovative treatments that provide a better […]
Phio Pharmaceuticals Announces Regulatory Clearance of Clinical Trial to Treat Solid Tumors
Phio Pharmaceuticals has announced their clinical development partner, AgonOx, has received confirmation from the FDA […]
AbbVie and Immunome Announce Strategic Collaboration to Discover Multiple Novel Oncology Targets
AbbVie and Immunome, a clinical-stage biopharmaceutical company that utilizes its human memory B cell platform […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more